Improved survival in cystic fibrosis patients with severely impaired lung function
A forced expiratory volume in one second (FEV1) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2 years or less.
Gespeichert in:
| Veröffentlicht in: | Thorax 2012-02, Vol.67 (2), p.138-138 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 138 |
|---|---|
| container_issue | 2 |
| container_start_page | 138 |
| container_title | Thorax |
| container_volume | 67 |
| creator | Narwani, Vishal |
| description | A forced expiratory volume in one second (FEV1) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2 years or less. |
| doi_str_mv | 10.1136/thoraxjnl-2011-200357 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1781813191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4027102701</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2707-d4e2169ff7a084565ab23d6e1b512990835dd5ab558f4b192accb343ed6a09b43</originalsourceid><addsrcrecordid>eNqNkFFLwzAUhYMoOKc_QQj4XM1tmqR51Ol0MhREZW8hbVOX2bUzaev2782o-OzLvXD5zj2cg9A5kEsAyq_aZeP0dlVXUUwAwiCUiQM0goSnEY0lP0QjQhIScSr4MTrxfkUISQHECL3M1hvX9KbAvnO97XWFbY3znW9tjkubucZbjze6taZuPf627RJ70xtnqh226422Lmirrv7AZVfnrW3qU3RU6sqbs989Rm_Tu9fJQzR_vp9NrudRFgsioiIxMXBZlkKTNGGc6SymBTeQMYilJCllRRGOjKVlkoGMdZ5nNKGm4JrILKFjdDH8DQG-OuNbtWo6VwdLBSKFFChICBQbqDxE8c6UauPsWrudAqL29am_-tS-PjXUF3TRoLO-Nds_kXafigsqmHp6nyj2eDOVcnGrFoEnA5-tV_-0-AHalIWo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781813191</pqid></control><display><type>article</type><title>Improved survival in cystic fibrosis patients with severely impaired lung function</title><source>BMJ Journals - NESLi2</source><source>Alma/SFX Local Collection</source><creator>Narwani, Vishal</creator><creatorcontrib>Narwani, Vishal</creatorcontrib><description>A forced expiratory volume in one second (FEV1) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2 years or less.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thoraxjnl-2011-200357</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>asthma guidelines ; Asthma mechanisms ; bronchiectasis ; Cystic fibrosis ; exhaled airway markers ; lung physiology ; paediatric asthma ; paediatric lung disease ; Pharmaceutical industry</subject><ispartof>Thorax, 2012-02, Vol.67 (2), p.138-138</ispartof><rights>2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://thorax.bmj.com/content/67/2/138.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://thorax.bmj.com/content/67/2/138.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,778,782,3185,23558,27911,27912,77357,77388</link.rule.ids></links><search><creatorcontrib>Narwani, Vishal</creatorcontrib><title>Improved survival in cystic fibrosis patients with severely impaired lung function</title><title>Thorax</title><addtitle>Thorax</addtitle><description>A forced expiratory volume in one second (FEV1) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2 years or less.</description><subject>asthma guidelines</subject><subject>Asthma mechanisms</subject><subject>bronchiectasis</subject><subject>Cystic fibrosis</subject><subject>exhaled airway markers</subject><subject>lung physiology</subject><subject>paediatric asthma</subject><subject>paediatric lung disease</subject><subject>Pharmaceutical industry</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkFFLwzAUhYMoOKc_QQj4XM1tmqR51Ol0MhREZW8hbVOX2bUzaev2782o-OzLvXD5zj2cg9A5kEsAyq_aZeP0dlVXUUwAwiCUiQM0goSnEY0lP0QjQhIScSr4MTrxfkUISQHECL3M1hvX9KbAvnO97XWFbY3znW9tjkubucZbjze6taZuPf627RJ70xtnqh226422Lmirrv7AZVfnrW3qU3RU6sqbs989Rm_Tu9fJQzR_vp9NrudRFgsioiIxMXBZlkKTNGGc6SymBTeQMYilJCllRRGOjKVlkoGMdZ5nNKGm4JrILKFjdDH8DQG-OuNbtWo6VwdLBSKFFChICBQbqDxE8c6UauPsWrudAqL29am_-tS-PjXUF3TRoLO-Nds_kXafigsqmHp6nyj2eDOVcnGrFoEnA5-tV_-0-AHalIWo</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Narwani, Vishal</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20120201</creationdate><title>Improved survival in cystic fibrosis patients with severely impaired lung function</title><author>Narwani, Vishal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2707-d4e2169ff7a084565ab23d6e1b512990835dd5ab558f4b192accb343ed6a09b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>asthma guidelines</topic><topic>Asthma mechanisms</topic><topic>bronchiectasis</topic><topic>Cystic fibrosis</topic><topic>exhaled airway markers</topic><topic>lung physiology</topic><topic>paediatric asthma</topic><topic>paediatric lung disease</topic><topic>Pharmaceutical industry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Narwani, Vishal</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Narwani, Vishal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved survival in cystic fibrosis patients with severely impaired lung function</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>67</volume><issue>2</issue><spage>138</spage><epage>138</epage><pages>138-138</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>A forced expiratory volume in one second (FEV1) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2 years or less.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><doi>10.1136/thoraxjnl-2011-200357</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-6376 |
| ispartof | Thorax, 2012-02, Vol.67 (2), p.138-138 |
| issn | 0040-6376 1468-3296 |
| language | eng |
| recordid | cdi_proquest_journals_1781813191 |
| source | BMJ Journals - NESLi2; Alma/SFX Local Collection |
| subjects | asthma guidelines Asthma mechanisms bronchiectasis Cystic fibrosis exhaled airway markers lung physiology paediatric asthma paediatric lung disease Pharmaceutical industry |
| title | Improved survival in cystic fibrosis patients with severely impaired lung function |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A03%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20survival%20in%20cystic%20fibrosis%20patients%20with%20severely%20impaired%20lung%20function&rft.jtitle=Thorax&rft.au=Narwani,%20Vishal&rft.date=2012-02-01&rft.volume=67&rft.issue=2&rft.spage=138&rft.epage=138&rft.pages=138-138&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thoraxjnl-2011-200357&rft_dat=%3Cproquest_cross%3E4027102701%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781813191&rft_id=info:pmid/&rfr_iscdi=true |